Nitrocard (Glyceryl Trinitrate)

Glyceryl trinitrate is a nitric‑oxide donor. After absorption through the skin, it is enzymatically converted to nitric oxide, which activates soluble guanylate cyclase in vascular smooth‑muscle cells. The resulting rise in cyclic GMP causes smooth‑muscle relaxation, leading to arterial and venous dilation, lower blood pressure, and reduced myocardial oxygen demand.

The specific dose and duration of Nitrocard therapy are determined by the prescribing clinician based on the patient’s condition, severity of symptoms, and response to treatment. Dosage may be adjusted during titration, and the product is supplied as a transdermal patch that the prescriber selects according to therapeutic need.

Safety data for Nitrocard during pregnancy and lactation are limited. The product should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Healthcare providers should discuss individual risk factors and consider alternative therapies when appropriate.

To order Nitrocard, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Nitrocard belongs to the organic nitrate class, offering rapid vasodilation and symptom relief, which differs from beta‑blockers that reduce heart rate and calcium‑channel blockers that affect myocardial contractility. Compared with other nitrates, Nitrocard’s transdermal delivery provides steady plasma levels and avoids the peaks and troughs associated with oral or sublingual formulations.

Nitrocard patches should be stored at room temperature, below 25 °C, in their original packaging. Protect them from moisture, direct sunlight, and sources of external heat, which can increase drug release. Keep the product out of reach of children and dispose of used patches according to local regulations.

Nitrocard is applied to clean, dry, hair‑free skin on the upper torso or upper arm. The patch is pressed firmly for several seconds to ensure adhesion and left in place for the prescribed duration, usually 12–24 hours, after which a new patch is applied to a different site to avoid skin irritation.

The most serious risks include severe hypotension, which can cause dizziness, syncope, or shock; myocardial infarction in patients with unstable coronary disease; and rare occurrences of methemoglobinemia that impair oxygen delivery. Patients should be instructed to seek immediate medical attention if they experience fainting, chest pain, or signs of allergic reaction.

Nitrocard is contraindicated in patients with known hypersensitivity to glyceryl trinitrate or any component of the patch, in those who have taken phosphodiesterase‑5 inhibitors within the previous 24‑48 hours, and in individuals with severe anemia, increased intracranial pressure, or uncompensated heart failure where rapid preload reduction could be harmful.